Insulet (PODD) Tops Q3 EPS by 12c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- KBR names its Mission Technology Solutions spinoff Trinzic
- Wall Street ends sharply higher, lifted by soaring Microsoft
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Insulet Corporation (PODD) PT Raised to $234 at Barclays
November 11, 2024 5:53 AM ESTBarclays analyst Matt Miksic raised the price target on Insulet Corporation (NASDAQ: PODD) to $234.00 (from $220.00) while maintaining a Equalweight rating.
The analyst comments "PODD Rallies on Q3 Beat, Fueled by International (+$19MM), Drug Delivery (+$7MM) and Rising Expectations for the T2 Pump Launch: Mgmt delivered a strong beat to vs. our estimates and Bloomberg... More
Insulet Corporation (PODD) PT Raised to $270 at BTIG
November 8, 2024 5:13 AM ESTBTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $270.00 (from $260.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q3 revenue of $543.9M (+25.7% y/y), beating consensus estimates of $519.5M and exceeding the ~$510-$524M sales guide. This was driven by a large beat in International Omnipod sales. U.S. Omnipod revenue of $395.6M came in ~$4M higher than expected (cons. $391.9M) while OUS Omnipod revenue of $138M was ~$15M above the Street's forecast (cons. $123.3M). Drug Delivery sales were $10.3M. The full year sales guide... More
